{"id":3114,"date":"2015-09-22T12:30:00","date_gmt":"2015-09-22T12:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/valberedning-i-xvivo-perfusion-ab-publ-9\/"},"modified":"2015-09-22T12:30:00","modified_gmt":"2015-09-22T12:30:00","slug":"valberedning-i-xvivo-perfusion-ab-publ-9","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/","title":{"rendered":"Valberedning i XVIVO Perfusion AB (publ)"},"content":{"rendered":"<p><span>F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2016:<\/p>\n<p> <\/span><\/p>\n<p><span>G\u00f6sta Johannesson, f\u00f6retr\u00e4der Bure Equity AB<br \/><\/span><span>Martin Lewin, f\u00f6retr\u00e4der Eccenovo AB,<br \/><\/span><span>Thomas Olausson,<br \/><\/span><\/p>\n<p><span><\/span><span>Utn\u00e4mningen har skett enligt den instruktion avseende principer f\u00f6r utseende av valberedning i bolaget som fastst\u00e4lldes vid \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) den 23 april 2015.<br \/>\u00a0<br \/> <\/span><\/p>\n<p><span>\u00c5rsst\u00e4mma i XVIVO Perfusion AB (publ) kommer att h\u00e5llas den 3 maj 2016 i G\u00f6teborg. Aktie\u00e4gare som \u00f6nskar f\u00e5 \u00e4rende behandlat p\u00e5 st\u00e4mman kan skriftligen beg\u00e4ra detta hos styrelsen. S\u00e5dan beg\u00e4ran om behandling av \u00e4rende skickas till XVIVO Perfusion AB (publ), Att: Styrelsens ordf\u00f6rande, Box 53015, 400 14 G\u00f6teborg och m\u00e5ste inkomma till styrelsen senast sju veckor f\u00f6re st\u00e4mman, eller i vart fall i s\u00e5 god tid att \u00e4rendet, om s\u00e5 kr\u00e4vs, kan upptas i kallelsen till st\u00e4mman.<\/p>\n<p> <\/span><\/p>\n<p><span>G\u00f6teborg 22 september 2015<\/span><\/p>\n<p><span>XVIVO Perfusion AB (publ)<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>Informationen l\u00e4mnades f\u00f6r publicering den\u00a022\u00a0september 2015 kl. 14:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2016: G\u00f6sta Johannesson, f\u00f6retr\u00e4der Bure Equity ABMartin Lewin,&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3114","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-nomination"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valberedning i XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedning i XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2016: G\u00f6sta Johannesson, f\u00f6retr\u00e4der Bure Equity ABMartin Lewin,...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ-9\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ-9\\\/\",\"name\":\"Valberedning i XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-09-22T12:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ-9\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ-9\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/valberedning-i-xvivo-perfusion-ab-publ-9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valberedning i XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedning i XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/","og_locale":"en_US","og_type":"article","og_title":"Valberedning i XVIVO Perfusion AB (publ) - XVIVO","og_description":"F\u00f6ljande personer har utsetts att ing\u00e5 i XVIVO Perfusions valberedning inf\u00f6r \u00e5rsst\u00e4mman 2016: G\u00f6sta Johannesson, f\u00f6retr\u00e4der Bure Equity ABMartin Lewin,...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/","name":"Valberedning i XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-09-22T12:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/valberedning-i-xvivo-perfusion-ab-publ-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Valberedning i XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}